Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | AKT2 | P31751 | 12/20 | 0.63 |
| ▸ | GSK3B | P49841 | 6/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949413 | 0.83 | JAK3 (0.61) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL3952915 | 0.83 | JAK3 (0.67) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL31550436 | 0.83 | JAK3 (0.93) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL1818852 | 0.83 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL3959075 | 0.81 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL2018963 | 0.81 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL1048998 | 0.81 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL19011777 | 0.81 | JAK3 (0.58) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL24804215 | 0.81 | ENPP1 (0.71) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL322769 | 0.81 | JAK3 (0.72) | JAK3HTR2CAKT2GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| CN-119101069-A | Spiro compounds and uses thereof | 轩竹生物科技股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885HTR2C 3411/4885AKT2 1555/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885HTR2C 3411/4885AKT2 1555/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | JAK3 4430/4885HTR2C 4334/4885AKT2 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.